Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years.
- DOI
- 10.1016/j.ard.2026.06.029
- Published
- 2026 Jul 28
- Container
- Annals of the rheumatic diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ard.2026.06.029,
title = {Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years.},
author = {Schmidt WA and Setty AR and Dejaco C and Rubbert-Roth A and Cid MC and Ishii T and Christ L and Joshi AD and Zerad N and Kadakia A and Zhao S and Zhao W and Lagunes I and Phillips C and Blockmans D and Merkel PA and SELECT-GCA study group},
year = {2026},
journal = {Annals of the rheumatic diseases},
doi = {10.1016/j.ard.2026.06.029},
url = {https://doi.org/10.1016/j.ard.2026.06.029}
}RIS
TY - JOUR TI - Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years. AU - Schmidt WA AU - Setty AR AU - Dejaco C AU - Rubbert-Roth A AU - Cid MC AU - Ishii T AU - Christ L AU - Joshi AD AU - Zerad N AU - Kadakia A AU - Zhao S AU - Zhao W AU - Lagunes I AU - Phillips C AU - Blockmans D AU - Merkel PA AU - SELECT-GCA study group PY - 2026 JO - Annals of the rheumatic diseases DO - 10.1016/j.ard.2026.06.029 UR - https://doi.org/10.1016/j.ard.2026.06.029 ER -
APA
WA, S., AR, S., C, D., A, R., MC, C., T, I., L, C., AD, J., N, Z., A, K., S, Z., W, Z., I, L., C, P., D, B., PA, M., & group, S. S. (2026). Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years.. Annals of the rheumatic diseases. https://doi.org/10.1016/j.ard.2026.06.029
Source records
- pubmed · retrieved 2026-09-25T06:48:37.626Z